《新股消息》中國抗體製藥-B(03681.HK)明起招股 入場費2,909.02元(更正)
中國抗體製藥-B(03681.HK)公布招股詳情,計劃以每股7.6元至9.6元發行約1.82億股,當中10%於香港公開發售,集資最多17.48億元,每手300股入場費約2,909.02元。中金公司及東方證券為其聯席保薦人。
該公司將於明日(31日)起至下周二(11月5日)招股,預期11月12日上市。是次引入兩名基石投資者雲南白藥(000538.SZ)及瑞捷軟件科技,合共投資6,000萬美元,設六個月禁售期,其中雲南白藥認購5,000萬美元等值股份。
以招股價中位數每股8.6元計,集資淨額為約14.61億元,所得約50%用於研發及商業化其核心產品;40%用於建設蘇州生產基地;以及10%用作營運資金等。
董事會主席兼首席執行官梁瑞安表示,未來將繼續研發用於治療免疫性疾病的新型藥物,令產品組合多元化,並盡快商業化旗艦產品SM03,除海口生產基地外,亦計劃興建蘇州生產基地,以應付未來商業化所需要的生產需求。
(更正:2019-10-30 18:01:14 《新股消息》中國抗體製藥-B
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.